Side-by-side · Research reference

CortagenvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/35 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Cortagen

Bioregulatory Tetrapeptide · Khavinson-School

TetrapeptideStructure

↓ LPO productsAntioxidant effectKozina 2007

AnimalEvidence level

Injectable · Animal models

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Cortagen

VIP

Primary target

Cerebral cortex tissue — molecular targets under investigation

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007 Anisimov 2004

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

—

Yes — exogenous VIP acts as physiological agonist

Origin

Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Cortagen

VIP

Animal model dose (rat)

Injection protocol (dose not specified in abstracts)

Multiple injections over study period.

—

Avian model dose (chicken)

40-day injection courseKuznik 2008

Compared to epithalon in hypophysectomized and aged birds.

—

Human peripheral nerve study

Therapeutic course (protocol details not provided)

Posttraumatic recovery context — reference cited but not detailed.

—

Evidence basis

Animal mechanistic studies

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Route

Injectable (inferred from animal protocols)

—

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

—

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

04Side Effects & Safety

Parameter

Cortagen

VIP

Antioxidant suppression

Suppression of antioxidant activity noted alongside LPO reductionKozina 2007

Mechanism unclear — possible homeostatic adaptation.

—

Immune/hemostasis effects

No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008

Epithalon reversed deficits; cortagen did not.

—

Human safety data

No adverse events reported in peripheral nerve recovery context

Limited detail in available abstracts.

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Cortagen

—

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Cortagen

—

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Cortagen

VIP

1. Preparation

Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Storage

—

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.